<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959815</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00074818</org_study_id>
    <nct_id>NCT01959815</nct_id>
  </id_info>
  <brief_title>Novel Screening Strategies for Scleroderma PAH</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with scleroderma can develop heart failure due to high blood pressure in the lungs
      (a condition called pulmonary arterial hypertension). It is important to find pulmonary
      arterial hypertension early, so that it can be treated before heart failure develops.
      However, the tests that we now use to find the earliest form of this disease in scleroderma
      patients are not good enough. This study will examine whether tests performed during exercise
      can improve our ability to find early pulmonary arterial hypertension. The study will also
      try to identify genes that are responsible for the development of pulmonary arterial
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of pulmonary arterial hypertension</measure>
    <time_frame>Two years after enrollment.</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Scleroderma and diagnosed PAH</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Low risk&quot; scleroderma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;High risk&quot; scleroderma</arm_group_label>
  </arm_group>
  <biospec_descr>
    <textblock>
      Blood samples will be drawn at rest and during exercise.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers will be recruited from scleroderma clinics, pulmonary hypertension clinics, and
        (for healthy volunteers) the Ann Arbor area.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30 years or older;

          -  diagnosis of limited or diffuse scleroderma (American College of Rheumatology
             criteria)

          -  for the &quot;high risk&quot; group, one of the following features:

               -  resting transthoracic echocardiogram showing elevated right-sided pressures
                  within previous 3 months [tricuspid regurgitation (TR) jet &gt;2.8 m/s or evidence
                  of right ventricular dysfunction]

               -  pulmonary function testing (PFT) showing abnormal diffusing capacity of carbon
                  monoxide (DLCO) not due to significant interstitial lung disease (DLCO&lt;60%
                  predicted or FVC: DLCO ratio &gt;1.4)

        Exclusion Criteria:

          -  Pregnancy

          -  prior diagnosis of pulmonary hypertension

          -  treatment with endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or
             prostacyclin analogues

          -  previous diagnosis of obstructive lung disease or pulmonary thromboembolic disease

          -  current smoker

          -  significant valvular disease

          -  resting echocardiogram showing left ventricular ejection fraction&lt;50% within previous
             3 months

          -  resting echocardiogram showing significant (greater than Grade I) diastolic
             dysfunction

          -  pulmonary emboli (past or present).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann Johnson, BSN</last_name>
    <phone>866-963-3587</phone>
    <email>cvc-ph-research@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Johnson, BSN</last_name>
      <phone>866-963-3587</phone>
      <email>cvc-ph-research@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Visovatti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>September 17, 2017</last_update_submitted>
  <last_update_submitted_qc>September 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Scott Visovatti, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

